Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria
Liya Wang(Wilmington University), Lisa A. Beck(University of Rochester Medicine), Vincent J. Willey(Wilmington University), Judith J. Stephenson(Wilmington University), Abhishek Kavati(Pfizer (United States)), Brandee Paknis(Novartis (United States)), Jonathan A. Bernstein(Bernstein Clinical Research Center), Qing Huang(Wilmington University), Benjamin Ortiz(Harlem Hospital Center), Xuehua Ke(Wilmington University), Debra Wertz(Wilmington University)
Cited by 14
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k